FutureWise Research, a leading global market intelligence firm, today released a landmark report on Plasmid DNA Manufacturing ...

Genenta & Anemocyte ink partnership to advance off-the-shelf LVV Plasmid DNA production: Milan Monday, October 27, 2025, 14:00 Hrs [IST] Genenta Science, a pioneer company in immu ...

Monday that a global tier-one pharmaceutical partner had started dosing patients in a phase one and two US clinical trial ...

Genenta Science (Nasdaq: GNTA), a pioneer Company in immuno-oncology, and ANEMOCYTE, a leading provider of advanced therapy and nucleic acids solutions, today announced a strategic collaboration with ...

Genenta Science shares surged by more than double Friday after the company said it has partnered with Anemocyte to collaborate on its plasmid DNA technology platform. The stock was briefly halted from ...

Once an antibody latches on to a pathogen, broadly neutralizing antibodies inactivate it (as their name implies). This is ...

The company says the system can benefit pharmaceutical and biotech firms seeking rapid feedback on drug candidates or genome editing.

OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces it has been recognised as a Champion in the ‘Cell & Gene Therapy’ category at the 2025 CDMO Leadership ...

OXB to participate in upcoming investor conferences and events Oxford, UK – 27 October 2025: OXB (LSE: OXB), a global quality and innovation-led ...

IMNN-001 program is currently advancing its OVATION 3 pivotal Phase 3 trial per planLAWRENCEVILLE, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- ...

Genenta Science (Nasdaq: GNTA), a pioneer Company in immuno-oncology, and ANEMOCYTE, a leading provider of advanced therapy and nucleic acids solutions, today ...

An increasing demand for gene therapies is focusing the industry on enhancing production capabilities, transitioning from ...